Federal health authorities in the United States have issued a warning to Dr. Patrick Soon-Shiong, a noted biotech billionaire and CEO of ImmunityBio, concerning misleading claims made about the company's cancer treatment drug, Anktiva. This warning raises critical issues related to drug marketing regulations.
The FDA's warning stems from comments made by Soon-Shiong during a podcast, where he discussed Anktiva's potential not only for treating bladder cancer, for which it has been approved since 2024, but also as a possible treatment or even cure for various other cancers, including lung and pancreatic cancers.
The FDA expressed concern that these assertions, disseminated through both a podcast and a television advertisement, convey a misleading impression of the drug's capabilities. Moreover, the FDA pointed out the lack of information regarding the possible side effects associated with Anktiva, such as urinary tract infections and chills, which are necessary for providing balanced drug information as required by law.
In the wake of the FDA's letter, the stock value of ImmunityBio plummeted by more than 24 percent. The FDA's warning was formally addressed to ImmunityBio's CEO, Richard Adcock, giving the company 15 days to rectify the misleading information provided in its communications.
ImmunityBio's spokesperson indicated that the company takes the FDA's warning seriously and is committed to working collaboratively with the agency to resolve the outlined concerns.
Previously, under the Trump administration, a focus on tightening regulations regarding drug advertisements led to more scrutiny of statements made by pharmaceutical executives in various media appearances, including podcasts and television.
